CYP2C19

The 3X4 Genetics Test + Blueprint Report provides 36 key insights and practical, personalized recommendations for patients to start taking control of their health.

The PgX (Pharmacogenomic) Test examines a patient's inherited genes to detect variations that may impact how a drug is broken down, absorbed, and used within the body.

The DetoxiGenomic® Profile uses genomic testing to identify a patient's risk for chemical sensitivities, oxidative stress, and the ability to handle various medications.

MedCheck gives insights into a patient's responsiveness to different medications and the likelihood of side effects and treatment failure. It provides insight into how a patient metabolizes, transports, and binds specific drugs, allowing physicians to prescribe medications that are most likely to prove effective with minimal side effects.

This test detects variations in the CYP2C19 gene. It helps identify patients with an increased or decreased metabolism of clopidogrel (Plavix®). This test can be ordered with any Boston Heart genetics test. Please be advised that Boston Heart Diagnostics policy states that practitioners are unable to order labs on themselves or their immediate family members.